ERBB2 and breast cancer: Third, high tumor-infiltrating lymphocytes (TILs) counts and immune-related gene expression signatures in the primary tumor are consistently associated with better survival in triple-negative breast cancer and HER2-positive breast cancer (15, 17–19).